patent/WO-02053171-A3

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02053171-A3

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f8182b19573e57c5d18957a5cd70e00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cda5caa867afd93e1ef82a86e64158e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0a0b9a34595194f0b0e9758ba511dc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9248d147fa3c26ff6a4e82ce0009203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d6b7303da047abb41be9b386d4c5346
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-205
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6881 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-423 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
filingDate	2001-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_732e04ff87c972c2ecebe31b66672da0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa3cd426c16c17d832c68b0550057d56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da26100dd08d7dc9dcd9a4d9cb88b5e1
publicationDate	2003-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	WO-02053171-A3
titleOfInvention	Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity
abstract	The invention relates to the use of intermediate-conductance, calcium-activated potassium channels and/or the nucleic acids coding for the same, from humans or mice, for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity. The invention also relates to the use of the same for identifying pharmacologically active substances. The invention further relates to the use of modulators of intermediate-conductance, calcium-activated potassium channels for the diagnosis, prevention and/or treatment of illnesses associated with disturbed keratinocyte activity.
priorityDate	2000-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate

Subject

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9811139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4569935-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0037422-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9925347-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4680296-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9718332-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0034248-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11209302-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0033834-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2273873-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0034228-A1

http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226409109
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3641960

Total number of triples: 73.